We are live on ! Find out more
PRVB

Provention Bio, Inc. Common Stock

Delisted

PRVB was delisted on the 26th of April, 2023.

100 hedge funds and large institutions have $284M invested in Provention Bio, Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 47 increasing their positions, 28 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

156% more call options, than puts

Call options by funds: $5.1M | Put options by funds: $1.99M

68% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 28

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

4% less capital invested

Capital invested by funds: $294M → $284M (-$10.5M)

6% less funds holding

Funds holding: 106100 (-6)

38% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 16

Holders
100
Holders Change
-6
Holders Change %
-5.66%
% of All Funds
2.02%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
10
Increased
47
Reduced
28
Closed
16
Calls
$5.1M
Puts
$1.99M
Net Calls
+$3.11M
Net Calls Change
-$3.66M
Name Holding Trade Value Shares
Change
Change in
Stake
First Trust Advisors
26
First Trust Advisors
Illinois
$1.55M +$1.53M +120,969 New
California Public Employees Retirement System
27
California Public Employees Retirement System
California
$1.38M +$175K +13,887 +15%
Swiss National Bank
28
Swiss National Bank
Switzerland
$1.1M
California State Teachers Retirement System (CalSTRS)
29
California State Teachers Retirement System (CalSTRS)
California
$924K +$103K +8,140 +13%
Group One Trading
30
Group One Trading
Illinois
$902K +$15.1K +1,199 +2%
Macquarie Group
31
Macquarie Group
Australia
$898K
State of Wisconsin Investment Board
32
State of Wisconsin Investment Board
Wisconsin
$872K
Citadel Advisors
33
Citadel Advisors
Florida
$796K +$374K +29,645 +91%
Morgan Stanley
34
Morgan Stanley
New York
$782K +$351K +27,774 +84%
SPC
35
Sigma Planning Corp
Michigan
$752K -$5.05K -400 -0.7%
AllianceBernstein
36
AllianceBernstein
Tennessee
$674K -$24K -1,900 -3%
Osaic Holdings
37
Osaic Holdings
Arizona
$669K +$445K +35,223 +208%
RhumbLine Advisers
38
RhumbLine Advisers
Massachusetts
$652K -$75.6K -5,985 -11%
Marshall Wace
39
Marshall Wace
United Kingdom
$598K -$2.44M -192,928 -81%
Bank of America
40
Bank of America
North Carolina
$571K -$224K -17,735 -29%
WAM
41
Wealthspire Advisors (Maryland)
Maryland
$554K -$189K -15,000 -26%
UBS Group
42
UBS Group
Switzerland
$551K -$47.9K -3,791 -8%
JGC
43
J. Goldman & Co
New York
$549K -$275K -21,803 -34%
TRCT
44
Tower Research Capital (TRC)
New York
$516K +$482K +38,147 +1,813%
New York State Common Retirement Fund
45
New York State Common Retirement Fund
New York
$498K
BAAM
46
Baker Avenue Asset Management
California
$465K -$139K -11,000 -23%
Wells Fargo
47
Wells Fargo
California
$439K -$152K -12,041 -26%
FAM
48
Fred Alger Management
New York
$388K -$187K -14,791 -33%
Deutsche Bank
49
Deutsche Bank
Germany
$368K +$56.4K +4,463 +18%
WCA
50
Windsor Creek Advisors
Vermont
$366K +$231K +18,300 +180%

PRVB Hedge Fund Activity: Q3 2020 in Review

100 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Provention Bio, Inc. Common Stock (PRVB) for Q3 2020, worth a combined $284M — down 3.6% from $294M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of PRVB and 10 opened new positions — a net loss of 6 holders — while 28 trimmed existing stakes and 47 added.

The largest buyer was Gilder Gagnon Howe & Co, adding an estimated $11.4M. The largest seller was Citigroup, cutting an estimated $7.22M.

  • 100 institutional investors held Provention Bio, Inc. Common Stock (PRVB) as of Q3 2020, down from 106 in Q2 2020.
  • Funds reported $284M of Provention Bio, Inc. Common Stock stock for Q3 2020, down 3.6% quarter-over-quarter.
  • 10 funds opened new Provention Bio, Inc. Common Stock positions in Q3 2020 and 16 closed out, a net change of -6 holders.
  • The largest Provention Bio, Inc. Common Stock buyer in Q3 2020 was Gilder Gagnon Howe & Co, an estimated $11.4M added.
  • The largest Provention Bio, Inc. Common Stock seller in Q3 2020 was Citigroup, an estimated $7.22M sold.

Based on aggregated 13F filings for Q3 2020.